PATH vs TLSIW · P/E 19, rev $1.61B vs rev $29.4M
Uipath Inc (PATH) versus TriSalus Life Sciences Inc. (TLSIW) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
TriSalus Life Sciences Inc. (TLSIW) common stock listed on NASDAQ.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported TLSIW revenue for 2024-12-31 was $29.4M. Net income was -$30.0M. Revenue was up 59.0% from 2023-12-31 to 2024-12-31. TLSIW currently screens at market cap $0.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. TLSIW currently screens at market cap $0.
Not investment advice. Open the PATH and TLSIW stock pages for the full models.
Not investment advice.